Answers are grounded in this paper and cite their sources.
Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth characteristics and a minimal risk of detrimental side effects.
No takes yet. Share an insight, caveat, or question.
Santegoets et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: